NCT06069726: An ongoing trial by Duke University
This trial is ongoing. It must report results 3 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06069726 |
|---|---|
| Title | A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 21, 2024 |
| Completion date | Jan. 1, 2028 |
| Required reporting date | Dec. 31, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |